 |
|
|
| |
Safety and Effectiveness From the CARISEL Study: Phase 3b Hybrid-III
Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into
European Clinical Settings
|
| |
| |
AIDS 2022 July 29- Aug 1 Montreal
Celia Jonsson-Oldenbüttel1,2, Jade Ghosn3,4, Marc van der Valk5, Eric Florence6, Francisco Vera7, Mounir Ait-Khaled8, Gilda Bontempo9, Christine Latham9, Cassidy A. Gutner9,
Supriya Iyer10, Rebecca DeMoor11, Martin Gill12, Maggie Czarnogorski9, Jean van Wyk8
1MUC Research GmbH, Munich, Germany; 2MVZ München am Goetheplatz, Munich, Germany; 3Université de Paris, INSERM UMR 1137 IAME, Paris, France; 4Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-
Claude Bernard, Paris, France; 5Amsterdam UMC, Department of Infectious Diseases, University of Amsterdam, Amsterdam, the Netherlands; 6Instituut voor Tropische Geneeskunde, Antwerp, Belgium; 7Hospital General Universitario
de Santa Lucía, Murcia, Spain; 8ViiV Healthcare, Brentford, United Kingdom; 9ViiV Healthcare, Research Triangle Park, NC, United States; 10GlaxoSmithKline, Bangalore, India; 11GlaxoSmithKline, Collegeville, PA, United States;
12GlaxoSmithKline, Brentford, United Kingdom
|
| |
|
|
|
|
|
